Back to news

Palatin Technologies Presents Compelling Preclinical Data on Next-Generation MC4R-Selective Peptide Agonists at ObesityWeek® 2026

PR Newswire•16/11/2026•07:30 ET
0

Key Highlights

  • ➤PL2001 selected as lead candidate, with first-in-human studies targeted for H1 2027
  • ➤MC4R selectivity exceeded 100-fold to 200-fold over MC1R in functional assays
  • ➤PL2001 produced significant dose-dependent weight and food-intake reductions after one dose
  • ➤Lipidated peptides showed half-lives exceeding 168 hours in dogs, supporting less-frequent dosing
  • ➤PL1001 showed no observed heart-rate or blood-pressure effects at efficacious preclinical doses

Expert Statements

Carl Spana, President and Chief Executive Officer of Palatin Technologies

“These findings represent an important advancement in our next-generation MC4R development programs and reinforce our confidence in our ability to deliver highly differentiated therapies.”

Carl Spana, President and Chief Executive Officer of Palatin Technologies

“We have demonstrated that potent MC4R agonism and meaningful preclinical weight-loss activity can be achieved with minimal to no MC1R activity, substantially reducing or eliminating hyperpigmentation, while our proprietary lipidation technology provides the potential for once-weekly or less frequent dosing. Combined with encouraging preliminary cardiovascular findings, these results directly address several of the most important limitations of existing MC4R therapies.”

Carl Spana, President and Chief Executive Officer of Palatin Technologies

“We believe that long-term efficacy, tolerability, and convenience will ultimately define the next generation of MC4R therapies. Our objective is not simply to replicate the benefits of existing treatments, but to meaningfully improve upon them. With PL2001 selected as a clinical development candidate and first-in-human studies targeted for the first half of 2027, we are increasingly confident in our ability to translate our differentiated preclinical science into potentially best-in-class treatments for patients with rare neuroendocrine obesity disorders.”

Palatin Technologies Presents Compelling Preclinical Data on Next-Generation MC4R-Selective Peptide Agonists at ObesityWeek® 2026 PR Newswire

* Novel peptide and long-acting lipidated peptide agonists demonstrate potent MC4R activity with minimal to no MC1R activity, supporting the potential to substantially reduce or eliminate hyperpigmentation * Significant reductions in body weight and food intake demonstrated in preclinical models, with encouraging preliminary cardiovascular finding * Proprietary lipidation technology supports once-weekly or potentially less frequent dosing; lead candidate PL2001 advancing toward first-in-human studies in the first half of 2027 PRINCETON, N.J., Nov. 16, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (Nasdaq: PTN), a biopharmaceutical company developing differentiated, next-generation melanocortin receptor agonists, today announced the presentation of new preclinical data highlighting the Company's proprietary MC4R-selective peptide agonist programs at ObesityWeek(®) 2026, being held November 14–17 in Washington, D.C.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in